Antidote Technologies
AI-powered clinical trial matching platform that connects patients to relevant trials and accelerates site recruitment.
What it does
Antidote is an AI-native clinical trial patient recruitment platform that matches patients with relevant clinical trials using AI-powered eligibility screening. Patients describe their condition and medical history through a structured questionnaire; Antidote's AI matches their profile against hundreds of active trial eligibility criteria and surfaces trials they may qualify for - connecting them directly to site coordinators. For pharmaceutical sponsors and CROs, Antidote provides a recruitment channel that accesses a large pool of patient-consented profiles for targeted trial recruitment outreach. AI capabilities include natural language eligibility criteria parsing that converts complex inclusion/exclusion criteria into structured matching logic, real-time patient-to-trial matching, and predictive enrollment modeling that forecasts recruitment timelines based on site and patient pool analysis.
Why AI-NATIVE
Antidote is AI-native - automated eligibility criteria parsing, intelligent patient-to-trial matching at scale, and predictive enrollment forecasting are the core product capabilities.
Best for
Pharmaceutical companies, biotech firms, and CROs use Antidote to accelerate clinical trial enrollment - AI patient matching reducing the time to find eligible participants and improving enrollment rates at sites with historically slow recruitment.
Limitations
Antidote's matching relies on patient-reported health information — accuracy of matches depends on how completely and accurately patients describe their condition, which varies and may not reflect clinical record data.
Antidote is a patient recruitment channel, not a complete recruitment solution — sponsors typically use multiple recruitment strategies (site referrals, registries, social media) alongside Antidote for full enrollment programs.
Simple eligibility criteria match well through AI; complex protocols with detailed laboratory value requirements and multi-stage screening procedures are harder to fully automate in patient-facing screening tools.
Alternatives by segment
Antidote enterprise contracts not published. Priced per trial and recruitment program scope. Pharmaceutical and CRO contracts negotiated annually.
